Provided by Tiger Trade Technology Pte. Ltd.

Tredegar

9.26
+0.33003.70%
Post-market: 9.21-0.0500-0.54%17:23 EST
Volume:143.88K
Turnover:1.33M
Market Cap:323.27M
PE:-5.96
High:9.35
Open:9.02
Low:9.02
Close:8.93
52wk High:9.43
52wk Low:6.25
Shares:34.91M
Float Shares:27.54M
Volume Ratio:0.86
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5541
EPS(LYR):-1.8798
ROE:1.26%
ROA:4.09%
PB:1.60
PE(LYR):-4.93

Loading ...

TG-17, Inc. trading resumes

TIPRANKS
·
Yesterday

TG Metals Drilling Confirms Gold Continuity and Growth Potential at Van Uden

TIPRANKS
·
Feb 04

TG Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Feb 03

Tredegar Corporation Files Initial Beneficial Ownership Statement for Controller Paul Goldschmiedt

Reuters
·
Jan 29

TG Metals Confirms High-Grade Gold Continuity at Van Uden and Expands Gold City Prospect

TIPRANKS
·
Jan 28

Major Tredegar Insiders Quietly Unload Matching Blocks of Shares

TIPRANKS
·
Jan 27

10% Owner James T. Gottwald Reports Disposal of Tredegar Corporation Common Shares

Reuters
·
Jan 26

Major Tredegar Insiders Quietly Unload a Wave of Shares

TIPRANKS
·
Jan 22

10% Owner William M. Gottwald Reports Disposal of Tredegar Corporation Common Shares

Reuters
·
Jan 22

TG Metals Upgrades Van Uden Drill Result as New Gold Discovery Extends Strike

TIPRANKS
·
Jan 20

TG Metals Extends Van Uden Gold Deposit with New Discovery to the South

TIPRANKS
·
Jan 20

TG Therapeutics Is Maintained at Neutral by Goldman Sachs

Dow Jones
·
Jan 15

TG Therapeutics price target raised to $39 from $37 at Goldman Sachs

TIPRANKS
·
Jan 15

TG Therapeutics Stock Climbs After The Bell: Here's Why

Benzinga
·
Jan 14

TG Therapeutics Announces Strong 2025 BRIUMVI Revenue Outlook

TIPRANKS
·
Jan 14

TG Therapeutics Issues 2026 Revenue Outlook; Shares Rise After Hours

MT Newswires Live
·
Jan 14

TG Therapeutics reports preliminary Q4 revenue $182M, consensus $182.38M

TIPRANKS
·
Jan 14

TG Therapeutics sees FY26 revenue $875M-$900M, consensus $895.63M

TIPRANKS
·
Jan 14

Is TG Therapeutics' (TGTX) JPM Briumvi Update Quietly Reframing Its MS Commercial Narrative?

Simply Wall St.
·
Jan 13

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

GlobeNewswire
·
Jan 12